Description: bioXXmed AG, an investment company, invests in biotechnology or medical technology companies with equity or debt capital. It engages in the development of products for the diagnosis, alleviation, or cure of diseases through investments. The company was formerly known as CytoTools AG and changed its name to bioXXmed AG in September 2022. bioXXmed AG was founded in 2000 and is based in Darmstadt, Germany.
Home Page: cytotools.de
Riedstrasse 2
Darmstadt,
64295
Germany
Phone:
49 6151 951 58 12
Officers
| Name | Title |
|---|---|
| Dr. Mark-André Freyberg | Chief Exec. Officer |
| Dr. Dirk Kaiser | Co-Founder & Chief Research Officer |
Exchange: XETRA
Country: DE
Currency: Euro (€)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0.3939 |
| Price-to-Sales TTM: | 164.0156 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 0 |